Putnam Investments buys $382,922,148 stake in Eli Lilly and Co (LLY)

Eli Lilly and Co (LLY) : Putnam Investments scooped up 402,175 additional shares in Eli Lilly and Co during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 4,773,400 shares of Eli Lilly and Co which is valued at $382,922,148.Eli Lilly and Co makes up approximately 0.90% of Putnam Investments’s portfolio.

Other Hedge Funds, Including , J.p. Marvel Investment Advisors reduced its stake in LLY by selling 147 shares or 0.25% in the most recent quarter. The Hedge Fund company now holds 59,386 shares of LLY which is valued at $4,763,945. Eli Lilly and Co makes up approx 1.59% of J.p. Marvel Investment Advisors’s portfolio.Montage Investments boosted its stake in LLY in the latest quarter, The investment management firm added 839 additional shares and now holds a total of 9,898 shares of Eli Lilly and Co which is valued at $794,018. Eli Lilly and Co makes up approx 0.54% of Montage Investments’s portfolio. Acrospire Investment Management sold out all of its stake in LLY during the most recent quarter. The investment firm sold 300 shares of LLY which is valued $24,480. Her Majesty The Queen In Right Of The Province Of Alberta… added LLY to its portfolio by purchasing 14,700 company shares during the most recent quarter which is valued at $1,215,984. Eli Lilly and Co makes up approx 0.02% of Her Majesty The Queen In Right Of The Province Of Alberta…’s portfolio. Highstreet Asset Management sold out all of its stake in LLY during the most recent quarter. The investment firm sold 8,511 shares of LLY which is valued $694,412.

Eli Lilly and Co closed down -0.52 points or -0.67% at $77.23 with 35,44,701 shares getting traded on Thursday. Post opening the session at $77.75, the shares hit an intraday low of $76.8 and an intraday high of $78 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.

On the company’s financial health, Eli Lilly and Co reported $0.86 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jul 26, 2016. Analyst had a consensus of $0.85. The company had revenue of $5404.80 million for the quarter, compared to analysts expectations of $5157.09 million. The company’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.90 EPS.

Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Eli Lilly and Co - Is it time to Sell?

Top Brokerage Firms are advising their investors on Eli Lilly and Co. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.